Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study
Yıl: 2021 Cilt: 38 Sayı: 1 Sayfa Aralığı: 15 - 21 Metin Dili: İngilizce DOI: 10.4274/tjh.galenos.2021.2020.0695 İndeks Tarihi: 31-01-2022
Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study
Öz: Objective: The defective interplay between coagulation and inflammation may be the leading cause of intravascular coagulation and organ dysfunction in coronavirus disease-19 (COVID-19) patients. Abnormal coagulation profiles were reported to be associated with poor outcomes. In this study, we assessed the prognostic values of antithrombin (AT) activity levels and the impact of fresh frozen plasma (FFP) treatment on outcome. Materials and Methods: Conventional coagulation parameters as well as AT activity levels and outcomes of 104 consecutive critically ill acute respiratory distress syndrome (ARDS) patients with laboratoryconfirmed COVID-19 disease were retrospectively analyzed. Patients with AT activity below 75% were treated with FFP. Maximum AT activity levels achieved in those patients were recorded. Results: AT activity levels at admission were significantly lower in nonsurvivors than survivors (73% vs. 81%). The cutoff level for admission AT activity was 79% and 58% was the lowest AT for survival. The outcome in those patients who had AT activity levels above 75% after FFP treatment was better than that of the nonresponding group. As well as AT, admission values of D-dimer, C-reactive protein, and procalcitonin were coagulation and inflammatory parameters among the mortality risk factors. Conclusion: AT activity could be used as a prognostic marker for survival and organ failure in COVID-19-associated ARDS patients. AT supplementation therapy with FFP in patients with COVID-19-induced hypercoagulopathy may improve thrombosis prophylaxis and thus have an impact on survival.
Anahtar Kelime: COVID-19 Hastalarında Antitrombin Seviyelerinin Prognostik Değeri ve Taze Donmuş Plazma Uygulamasının Prognoza Etkisi: Bir Retrospektif Çalışma
Öz: Amaç: Koagülasyon ve enflamasyon arasındaki etkileşim, koronavirüs hastalığı-19 (COVID-19) hastalarında damar içi pıhtılaşma ve organ disfonksiyonunun önde gelen nedeni olabilir. Anormal pıhtılaşma profillerinin kötü sonuçlarla ilişkili olduğu bildirilmiştir. Bu çalışmada antitrombin (AT) aktivite düzeylerinin prognostik değerini ve taze donmuş plazma (TDP) tedavisinin klinik sonlanım üzerine etkisini değerlendirdik. Gereç ve Yöntemler: Laboratuvarda doğrulanmış COVID-19 hastalığı olan 104 kritik akut solunum sıkıntısı sendromu (ARDS) hastasının geleneksel pıhtılaşma parametreleri, AT aktiviteleri ve klinik sonlanımları geriye dönük olarak analiz edildi. AT aktivitesi <%75 olan hastalara TDP uygulandı ve bu hastalarda ulaşılan en yüksek AT aktiviteleri kaydedildi. Bulgular: Giriş AT aktivitesi seviyeleri, ölenlerde yaşayanlara göre önemli ölçüde düşük kaydedildi (%73 vs. %81). Sağkalım için giriş AT aktivitesi eşik değeri %79, en düşük AT aktivitesi eşik değeri %58 olarak bulundu. TDP uygulamasından sonra AT aktivite düzeyleri %75 ve üzerinde olan hastalardaki klinik sonlanım, <%75 olan hastalardan daha iyiydi. AT’nin yanı sıra giriş D-dimer, C-reaktif protein ve prokalsitonin değerleri, mortalite risk faktörleri arasında yer alan koagülasyon ve enflamasyon parametreleriydi. Sonuç: AT aktivitesi, COVID-19 ile ilişkili ARDS hastalarında sağkalım ve organ yetmezliği için prognostik belirteç olarak kullanılabilir. COVID-19’un neden olduğu hiperkoagülopatili hastalarda TDP ile antitrombin uygulaması, tromboz profilaksisini iyileştirebilir ve böylelikle sağkalımı olumlu yönde etkileyebilir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844-847.
- 2. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180: 1-11.
- 3. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood 2018;131:845-854.
- 4. Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, Falco M, Albano G, Menicanti L. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020;18:1747-1751.
- 5. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020;395:1417-1418.
- 6. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020;18:1023-1026.
- 7. Hayakawa M, Yamakawa K, Kudo D, Ono K. Optimal antithrombin activity threshold for initiating antithrombin supplementation in patients with sepsis-induced disseminated intravascular coagulation: a multicenter retrospective observational study. Clin Appl Thromb Hemost 2018;24:874- 883.
- 8. Mintz PD, Blatt PM, Kuhns WJ, Roberts HR. Antithrombin III in fresh frozen plasma, cryoprecipitate, and cryoprecipitate-depleted plasma. Transfusion 1979;19:597-598.
- 9. World Health Organization. Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (nCoV) Infection Is Suspected: Interim Guidance. Geneva, WHO, 2020. Available at https://www.who.int/ publications-detail/clinical-management-of-severe-acute-respiratoryinfection- whennovel-coronavirus-(ncov)-infection-is-suspected.
- 10. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307:2526-2533.
- 11. Han H, Yang L, Liu R, Liu F, Wu KL, Li J, Liu XH, Zhu CL. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020;58:1116-1120.
- 12. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, Pesenti A, Peyvandi F, Tripodi A. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020;18:1738-1742.
- 13. Arachchillage DJ, Remmington C, Rosenberg A, Xu T, Passariello M, Hall D, Laffan AM, Patel BV. Anticoagulation with argatroban in patients with acute antithrombin deficiency in severe COVID-19. Br J Haematol (in press). doi: 10.1111/bjh.16927.
- 14. Dujardin RWG, Hilderink BN, Haksteen WE, Middeldorp S, Vlaar APJ, Thachil J, Müller MCA, Juffermans NP. Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients. Thromb Res 2020;96:308-312.
- 15. Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H. Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost 2014;12:1470-1479.
- 16. Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, Koga S, Mayumi T, Koike K, Gando S, Kushimoto S, Seki Y, Madoiwa S, Maruyama I, Yoshioka A; Japanese Society of Thrombosis Hemostasis/DIC Subcommittee. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010;125:6-11.
- 17. Sabbagh AH, Chung GK, Shuttleworth P, Applegate BJ, Gabrhel W. Fresh frozen plasma: a solution to heparin resistance during cardiopulmonary bypass. Ann Thorac Surg 1984;37:466-468.
- 18. Bharadwaj J, Jayaraman C, Shrivastava R. Heparin resistance. Lab Hematol 2003;9:125-131.
- 19. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA. Hematological findings and complications of COVID-19. Am J Hematol 2020;95:834-847.
- 20. Levy JH, Sniecinski RM, Welsby IJ, Levi M. Antithrombin: Anti-inflammatory properties and clinical applications. Thromb Haemost 2016;115:712-728.
- 21. Oelschlager C, Romisch J, Staubitz A, Stauss H, Leithauser B, Tillmanns H, Holschermann H. Antithrombin III inhibits nuclear factor κB activation in human monocytes and vascular endothelial cells. Blood 2002;99:4015- 4020.
- 22. Mansell A, Reinicke A, Worrall DM, O’Neill LA. The serine protease inhibitor antithrombin III inhibits LPS-mediated NFkappaB activation by TLR-4. FEBS Lett 2001;508:313-317.
- 23. Kountchev J, Bijuklic K, Bellmann R, Wiedermann CJ, Joannidis M. Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis. Crit Care 2005;9:596- 600.
- 24. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, Merdji H, Clere-Jehl R, Schenck M, Fagot Gandet F, Fafi-Kremer S, Castelain V, Schneider F, Grunebaum L, Anglés-Cano E, Sattler L, Mertes PM, Meziani F; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020;46:1089-1098.
| APA | Anaklı İ, Ergin Ozcan P, POLAT O, orhun g, ALAY G, Tuna V, ÇELİKSOY E, Kılıc M, Mercan M, ali a, Erdem S, ESEN F (2021). Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study. , 15 - 21. 10.4274/tjh.galenos.2021.2020.0695 |
| Chicago | Anaklı İlkay,Ergin Ozcan Perihan,POLAT OZLEM,orhun günseli,ALAY GÜLÇİN HİLAL,Tuna Verda,ÇELİKSOY EMRE,Kılıc Mehmet,Mercan Mutlu,ali achmet,Erdem Simge,ESEN FIGEN Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study. (2021): 15 - 21. 10.4274/tjh.galenos.2021.2020.0695 |
| MLA | Anaklı İlkay,Ergin Ozcan Perihan,POLAT OZLEM,orhun günseli,ALAY GÜLÇİN HİLAL,Tuna Verda,ÇELİKSOY EMRE,Kılıc Mehmet,Mercan Mutlu,ali achmet,Erdem Simge,ESEN FIGEN Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study. , 2021, ss.15 - 21. 10.4274/tjh.galenos.2021.2020.0695 |
| AMA | Anaklı İ,Ergin Ozcan P,POLAT O,orhun g,ALAY G,Tuna V,ÇELİKSOY E,Kılıc M,Mercan M,ali a,Erdem S,ESEN F Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study. . 2021; 15 - 21. 10.4274/tjh.galenos.2021.2020.0695 |
| Vancouver | Anaklı İ,Ergin Ozcan P,POLAT O,orhun g,ALAY G,Tuna V,ÇELİKSOY E,Kılıc M,Mercan M,ali a,Erdem S,ESEN F Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study. . 2021; 15 - 21. 10.4274/tjh.galenos.2021.2020.0695 |
| IEEE | Anaklı İ,Ergin Ozcan P,POLAT O,orhun g,ALAY G,Tuna V,ÇELİKSOY E,Kılıc M,Mercan M,ali a,Erdem S,ESEN F "Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study." , ss.15 - 21, 2021. 10.4274/tjh.galenos.2021.2020.0695 |
| ISNAD | Anaklı, İlkay vd. "Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study". (2021), 15-21. https://doi.org/10.4274/tjh.galenos.2021.2020.0695 |
| APA | Anaklı İ, Ergin Ozcan P, POLAT O, orhun g, ALAY G, Tuna V, ÇELİKSOY E, Kılıc M, Mercan M, ali a, Erdem S, ESEN F (2021). Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study. Turkish Journal of Hematology, 38(1), 15 - 21. 10.4274/tjh.galenos.2021.2020.0695 |
| Chicago | Anaklı İlkay,Ergin Ozcan Perihan,POLAT OZLEM,orhun günseli,ALAY GÜLÇİN HİLAL,Tuna Verda,ÇELİKSOY EMRE,Kılıc Mehmet,Mercan Mutlu,ali achmet,Erdem Simge,ESEN FIGEN Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study. Turkish Journal of Hematology 38, no.1 (2021): 15 - 21. 10.4274/tjh.galenos.2021.2020.0695 |
| MLA | Anaklı İlkay,Ergin Ozcan Perihan,POLAT OZLEM,orhun günseli,ALAY GÜLÇİN HİLAL,Tuna Verda,ÇELİKSOY EMRE,Kılıc Mehmet,Mercan Mutlu,ali achmet,Erdem Simge,ESEN FIGEN Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study. Turkish Journal of Hematology, vol.38, no.1, 2021, ss.15 - 21. 10.4274/tjh.galenos.2021.2020.0695 |
| AMA | Anaklı İ,Ergin Ozcan P,POLAT O,orhun g,ALAY G,Tuna V,ÇELİKSOY E,Kılıc M,Mercan M,ali a,Erdem S,ESEN F Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study. Turkish Journal of Hematology. 2021; 38(1): 15 - 21. 10.4274/tjh.galenos.2021.2020.0695 |
| Vancouver | Anaklı İ,Ergin Ozcan P,POLAT O,orhun g,ALAY G,Tuna V,ÇELİKSOY E,Kılıc M,Mercan M,ali a,Erdem S,ESEN F Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study. Turkish Journal of Hematology. 2021; 38(1): 15 - 21. 10.4274/tjh.galenos.2021.2020.0695 |
| IEEE | Anaklı İ,Ergin Ozcan P,POLAT O,orhun g,ALAY G,Tuna V,ÇELİKSOY E,Kılıc M,Mercan M,ali a,Erdem S,ESEN F "Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study." Turkish Journal of Hematology, 38, ss.15 - 21, 2021. 10.4274/tjh.galenos.2021.2020.0695 |
| ISNAD | Anaklı, İlkay vd. "Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study". Turkish Journal of Hematology 38/1 (2021), 15-21. https://doi.org/10.4274/tjh.galenos.2021.2020.0695 |
